Several targeted therapies that have enjoyed great success are Zelboraf (vemurafenib; formerly known as PLX4032) for treating advanced melanoma [7], monoclonal antibody trastuzumab for human epidermal growth factor receptor 2 (HER2) positive breast cancer [8], imatinib for break cluster region-abelson leukemia (BCR-Abl) positive chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) [9,10], and gefitinib and erlotinib for non-small cell lung cancer (NSCLC) [11]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.